Haya Taitel
Director/Miembro de la Junta en ENTERA BIO LTD. .
Fortuna: 36 000 $ al 30/04/2024
Perfil
Haya Taitel is an Independent Director at Entera Bio Ltd.
since 2023.
Previously, she worked as the Chief Commercial Officer at Kadmon Holdings, Inc. from 2018 to 2021.
She completed her undergraduate degree at The Hebrew University of Jerusalem and her graduate degree at Temple University School of Pharmacy.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
ENTERA BIO LTD.
0.05% | 01/03/2024 | 18 000 ( 0.05% ) | 36 000 $ | 30/04/2024 |
Cargos activos de Haya Taitel
Empresas | Cargo | Inicio |
---|---|---|
ENTERA BIO LTD. | Director/Miembro de la Junta | 07/06/2023 |
Antiguos cargos conocidos de Haya Taitel.
Empresas | Cargo | Fin |
---|---|---|
KADMON HOLDINGS, INC. | Corporate Officer/Principal | 01/11/2021 |
Formación de Haya Taitel.
Temple University School of Pharmacy | Graduate Degree |
The Hebrew University of Jerusalem | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ENTERA BIO LTD. | Health Technology |
Empresas privadas | 1 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Haya Taitel